. 2016 Nov 5;17(11):1845. doi: 10.3390/ijms17111845

Table 3.

Univariate and multivariate analysis of survival in 110 patients with NSCLC according to clinicopathologic factors and circulating mRNA levels of CK7, ELF3, EGFR and EphB4.

Clinicopathologic Factor		DFS							OS
		Total	Survival (mo.)	Univariate Analysis		Multivariate Analysis			Survival (mo.)	Univariate Analysis		Multivariate Analysis
		N	Survival (mo.)	χ2	p-Values	HR (95% CI)		p-Values	Survival (mo.)	χ2	p-Values	HR (95% CI)		p-Values
Age	<60	45	21.69 ± 6.90	2.577	0.108	1.604	0.842–3.057	0.151	22.67 ± 6.43	2.608	0.106	2.184	0.894–5.337	0.086
Age	≥60	65	20.66 ± 7.75	2.577	0.108	1.604	0.842–3.057	0.151	24.15 ± 7.76	2.608	0.106	2.184	0.894–5.337	0.086
Gender	Male	78	19.92 ± 6.85	4.447	0.035	0.237	0.098–0.574	0.001	22.65 ± 5.95	8.597	0.003	0.120	0.026–0.553	0.006
Gender	Female	32	23.91 ± 8.02	4.447	0.035	0.237	0.098–0.574	0.001	25.72 ± 9.50	8.597	0.003	0.120	0.026–0.553	0.006
Smoking	No	45	21.33 ± 7.95	0.580	0.446	0.456	0.215–0.969	0.041	23.96 ± 8.00	0.707	0.401	0.578	0.220–1.519	0.266
Smoking	Yes	65	20.91 ± 7.05	0.580	0.446	0.456	0.215–0.969	0.041	23.26 ± 6.74	0.707	0.401	0.578	0.220–1.519	0.266
Lesion site	Left lobe	50	20.94 ± 7.79	0.003	0.957	0.873	0.476–1.601	0.660	24.26 ± 7.74	0.254	0.615	0.933	0.409–2.130	0.869
Lesion site	Right lobe	60	21.20 ± 7.12	0.003	0.957	0.873	0.476–1.601	0.660	22.95 ± 6.83	0.254	0.615	0.933	0.409–2.130	0.869
Histopathological type	SCC	45	22.60 ± 7.85	2.286	0.131	1.374	0.654–2.888	0.401	24.76 ± 7.76	0.068	0.794	1.338	0.518–3.452	0.548
Histopathological type	ADC	65	20.03 ± 6.94	2.286	0.131	1.374	0.654–2.888	0.401	22.71 ± 6.82	0.068	0.794	1.338	0.518–3.452	0.548
Tumor size	≤3 cm	24	20.38 ± 6.28	0.833	0.361	0.894	0.421–1.897	0.769	24.12 ± 8.22	0.342	0.559	1.528	0.476–4.903	0.476
Tumor size	>3 cm	85	21.34 ± 7.73	0.833	0.361	0.894	0.421–1.897	0.769	23.47 ± 7.00	0.342	0.559	1.528	0.476–4.903	0.476
Differentiation	Well/Moderate	40	21.55 ± 6.92	0.016	0.898	0.685	0.326–1.439	0.318	23.80 ± 6.43	0.000	1.000	0.653	0.237–1.796	0.409
Differentiation	Poor	70	20.81 ± 7.70	0.016	0.898	0.685	0.326–1.439	0.318	23.40 ± 7.73	0.000	1.000	0.653	0.237–1.796	0.409
T stage	T2	93	20.92 ± 7.23	0.000	0.993	0.776	0.313–1.925	0.584	23.30 ± 6.92	0.269	0.604	0.410	0.120–1.407	0.156
T stage	T3	17	21.94 ± 8.45	0.000	0.993	0.776	0.313–1.925	0.584	24.88 ± 8.99	0.269	0.604	0.410	0.120–1.407	0.156
Lymph node status	N0	18	19.28 ± 4.99	0.585	0.444	0.757	0.256–2.243	0.616	20.39 ± 3.27	0.455	0.500	0.497	0.133–1.859	0.299
Lymph node status	N1–3	92	21.43 ± 7.76	0.585	0.444	0.757	0.256–2.243	0.616	24.16 ± 7.66	0.455	0.500	0.497	0.133–1.859	0.299
Distant metastasis	M0	108	20.82 ± 7.09	2.229	0.135	0.000	0.000–9.74 × 10²³³	0.968	23.28 ± 6.82	0.417	0.519	1.451	0.139–15.122	0.756
Distant metastasis	M1	2	35.00 ± 14.14	2.229	0.135	0.000	0.000–9.74 × 10²³³	0.968	38.00 ± 18.38	0.417	0.519	1.451	0.139–15.122	0.756
Clinical stage	I/II	56	21.96 ± 6.89	5.723	0.017	1.878	0.903–3.903	0.091	23.29 ± 6.58	1.075	0.300	1.418	0.532–3.781	0.486
Clinical stage	III/IV	54	20.17 ± 7.85	5.723	0.017	1.878	0.903–3.903	0.091	23.81 ± 7.95	1.075	0.300	1.418	0.532–3.781	0.486
Circulating CK7 mRNA	>2-fold	53	17.62 ± 7.95	82.565	1.02 × 10⁻⁹	132.315	10.691-1637.622	1.41 × 10⁻⁴	22.74 ± 9.00	36.447	1.57 × 10⁻⁹	91.148	3.863–2150.588	0.005
Circulating CK7 mRNA	Normal/low	57	24.30 ± 5.11	82.565	1.02 × 10⁻⁹	132.315	10.691-1637.622	1.41 × 10⁻⁴	24.30 ± 5.11	36.447	1.57 × 10⁻⁹	91.148	3.863–2150.588	0.005
Circulating ELF3 mRNA	>2-fold	54	17.87 ± 8.00	77.808	1.13 × 10⁻¹⁸	119.681	10.024–1428.965	1.56 × 10⁻⁴	22.89 ± 8.91	34.479	4.31 × 10⁻⁹	84.458	3.655–1951.764	0.006
Circulating ELF3 mRNA	Normal/low	56	24.18 ± 5.19	77.808	1.13 × 10⁻¹⁸	119.681	10.024–1428.965	1.56 × 10⁻⁴	24.18 ± 5.19	34.479	4.31 × 10⁻⁹	84.458	3.655–1951.764	0.006
Circulating EGFR mRNA	>2-fold	57	18.39 ± 8.51	67.452	2.16 × 10⁻¹⁶	101.954	8.565–1213.683	2.53 × 10⁻⁴	23.14 ± 9.13	29.888	4.58 × 10⁻⁸	72.525	3.178–1655.090	0.007
Circulating EGFR mRNA	Normal/low	53	23.98 ± 4.49	67.452	2.16 × 10⁻¹⁶	101.954	8.565–1213.683	2.53 × 10⁻⁴	23.98 ± 4.49	29.888	4.58 × 10⁻⁸	72.525	3.178–1655.090	0.007
Circulating EphB4 mRNA	>2-fold	52	17.69 ± 7.69	68.262	1.43 × 10⁻¹⁶	26.490	8.111–86.516	5.76 × 10⁻⁸	22.62 ± 8.88	30.619	3.14 × 10⁻⁸	19.010	4.487–80.547	6.40 × 10⁻⁵
Circulating EphB4 mRNA	Normal/low	58	24.12 ± 5.64	68.262	1.43 × 10⁻¹⁶	26.490	8.111–86.516	5.76 × 10⁻⁸	24.38 ± 5.34	30.619	3.14 × 10⁻⁸	19.010	4.487–80.547	6.40 × 10⁻⁵

SCC: squamous cell carcinoma; ADC: adenocarcinoma; DFS: disease free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; mo.: month; Normal: 0.5 ≤ 2^−ΔΔC^t ≤ 2; low: 2^−ΔΔC^t < 0.5.